Summary
Altimmune recently reported mixed data on their NasoShield and HepTcell programs. I take a look at the press release to extract the good and the bad.
The company reports new immuno-oncology pipeline products. It appears the company is branching off, but for what reason? I give my opinion on this new endeavor.
NasoVAX is still on track and so is my 2019 price target.
Altimmune (ALT) recently released updates on their NasoShield and HepTcell programs. Similar to the March 2018 data release, the company provided a mix of positive and negative information, but the negative appears to outweigh the positive. Since the press release, the share price has fallen to a new 52-week low of $2.02 and has only recovered a bit since (12/14/18). Besides the pipeline data, the company announced the addition of Adjusyn to the company’s pipeline. The company continues to have an unpredictable 2018 and it is leaving investors a bit confused on what pipeline product to have conviction in. I intend to interpret the press release and provide investors some potential scenarios spawned from this press release.
Company Overview
Altimmune is a clinical stage immunotherapeutic biotech company developing two cutting-edge vaccine delivery platforms, RespirVec and Densigen. Altimmune is currently designing and developing immunotherapeutic products envisioned to address a plethora of disease indications comprising of acute respiratory infections, chronic viral infections, and even cancer. The company’s goal is to offer therapeutic products that have distinguishing benefits over existing products.
